Communiqués Dova Pharmaceuticals, Inc.

Actions

DOVA

US25985T1025

Recherche biotechnologique et médicale

Temps Différé Nasdaq Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-0,07%	+269,92%

06/08/19	Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019
27/06/19	Transcript : Dova Pharmaceuticals, Inc. - Special Call

Communiqués

01/10/19	Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) on Behalf of Dova Shareholders and Encourages Dova Investors to Contact the Firm	PR
30/09/19	Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)	GL
25/09/19	Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference	GL
03/09/19	Dova Pharmaceuticals to Present at Upcoming Investor Conferences	GL
06/08/19	Dova Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference	GL
06/08/19	Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results	GL
30/07/19	Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019	GL
19/07/19	Dova Pharmaceuticals Announces DOPTELET® (avatrombopag) Now Commercially Available in the United States for Treatment of Chronic Immune Thrombocytopenia (ITP)	GL
27/06/19	Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)	GL
25/06/19	Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease	GL
24/06/19	Dova Pharmaceuticals Announces Four Presentations on Avatrombopag in Patients with Chronic Immune Thrombocytopenia at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress	GL
28/05/19	Dova Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference	GL
07/05/19	Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results	GL
30/04/19	Dova Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 7, 2019	GL
29/04/19	Dova Pharmaceuticals Receives Positive Opinion from CHMP for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease	GL
02/04/19	Dova Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference	GL
05/03/19	Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results	GL
19/02/19	Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019	GL
19/02/19	Dova Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference	GL
02/01/19	Dova Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference	GL
06/11/18	Dova Pharmaceuticals to Present at Upcoming Investor Conferences	GL
27/09/18	CORRECTING and REPLACING – Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)	GL
27/09/18	Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)	GL
26/09/18	Dova Pharmaceuticals to Present at Upcoming Investor Conferences	GL
11/09/18	Dova Pharmaceuticals to Host Investor & Analyst Day on September 20, 2018	GL